Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072114 | 1.00 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL10072177 | 1.00 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL3505858 | 1.00 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL31197400 | 1.00 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL12814326 | 0.91 | CES2 (0.52) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL2865178 | 0.89 | CES2 (0.72) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL11242983 | 0.88 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL8567370 | 0.88 | CES2 (0.64) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL2430018 | 0.87 | CES2 (0.68) | CES2KMT2AMAPTMEN1THRB | |
| SCHEMBL23064078 | 0.85 | CES2 (0.67) | CES2KMT2AMAPTMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130272978-A1 | DIHYDROXYACETONE MONOETHERS | MERCK PATENT GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084121-A1 | DIHYDROXYACETONE MONOETHER | MERCK PATENT GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130272978-A1 | DIHYDROXYACETONE MONOETHERS | GNPAT, UGT1A7, UGT1A3 | CES2 643/4885KMT2A 1575/4885MAPT 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.